Thales Introduces CipherTrust Intelligent Protection to Automate Security for Sensitive Data
Building on the success of the CipherTrust Data Security Platform, Thales has released CipherTrust Intelligent Protection, a new solution that further simplifies operational complexity and strengthens data security efforts with automated processes that discover, protect and control sensitive data anywhere. Faced with overwhelming data growth, organisations can use CipherTrust Intelligent Protection to safeguard all sensitive information without the added cost and complexity of traditional data protection products and services. Once the sensitive data has been discovered and classified based on vulnerability and other risk profiles, the new solution automatically protects at-risk data with encryption and robust access controls.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110005012/en/
©Thales
CipherTrust Intelligent Protection is a solution configuration within the Thales CipherTrust Data Security Platform that works together with CipherTrust Manager, CipherTrust Data Discovery and Classification, and CipherTrust Transparent Encryption –an all-in-one solution that delivers a unified approach. CipherTrust Intelligent Protection addresses the evolving challenges of regulatory compliance by facilitating accelerated time to compliance with automatic data protection controls. It also offers easy-to-use, pre-programmed tools to quickly and effectively secure unstructured sensitive data on-premises and in the cloud.
Reducing complexity in data protection with integrated automation
As organisations contend with expanding datasets, permanent work-from-home or hybrid office schemes, and the increased use of multi-cloud services, lack of visibility places their sensitive data at risk. Thales’s 2021 Data Threat Report found that the use of cloud-based infrastructure exposes new risks as an organisation’s data footprint expands and raises concerns about operational complexity. Less than a quarter (24%) of respondents said they have complete knowledge of where their data is stored. Configurable policies with built-in templates to rapidly discover and classify unstructured sensitive data can be used to protect data on-premises and in the cloud.
“Cloud computing services and data security requirements will only grow more complex as organisations work to keep pace with new and evolving work environments,” said Todd Moore, VP Encryption Products at Thales. “Increased operational complexity demands simplified security procedures, and CipherTrust Intelligent Protection makes it significantly easier for companies to safeguard data proactively based on known vulnerabilities and data privacy regulations, which reduces overall business risk. Intelligent Protection provides the automation so customers can confidently take data security measures into their own hands with an all-in-one solution.”
Accelerating time-to-compliance
Today’s businesses and organisations must remain in compliance with a broad range of regulations and mandates, including GDPR, CCPA, HIPAA, and PCI DSS. Data privacy laws and regulations are never static – new ones appear regularly and existing ones often get enhanced, making it difficult for you to keep pace. An integrated and automated solution helps eliminate blind spots and human error, making a considerable difference in complying with various regulations.
"This all-in-one solution combines the best of the Ground Labs' data discovery technology with Thales’ CipherTrust Data Security Platform to give organizations the power to automatically discover, classify and keep sensitive data secure, whether it's on-premises or in the cloud," said Stephen Cavey, co-founder and chief evangelist of Ground Labs. “Our partnership with Thales underscores our common mission to protect our customers, regardless of where they store their data - and through this collaboration, we can better meet the data security needs of customers today and in the future."
“Managing risk is becoming increasingly burdensome for IT leaders not only because of the volume and sophistication of cyber-attacks but also due to the operational complexity of managing disparate security products and services,” said Frank Dickson, Program Vice President, Security & Trust, IDC. “Truly integrated platforms that automate the discovery, classification and protection of sensitive data can help organisations reduce both hard costs and risks associated with stitching together multivendor solutions while addressing and mitigating soft costs by simplifying data security operations and compliance.”
Uncover and Close Security Gaps
Finding a way to rapidly identify data compliance gaps and potential security risks is of paramount importance. Using the high performance and accurate discovery engine is an extremely useful way to find data subject to regulations that organizations may not realize even exists. CipherTrust Data Discovery and Classification provides risk-based guidance on what specific data to encrypt. Linking this discovery process to CipherTrust Transparent Encryption provides organizations with a fast track to automatically uncover and close security gaps.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005012/en/
Contact information
PRESS
Thales, Media Relations
Security
Constance Arnoux
+33 (0)6 44 12 16 35
Constance.arnoux@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
